The objective of this study is to assess the clinical effectiveness of naltrexone versus acamprosate and placebo in alcohol dependent patients receiving psychotherapy. Analysis was conducted in accordance with the principles of systematic review, based on the Cochrane Collaboration guidelines and the guidelines of the Polish Agency for Health Technology Assessment. Calculations were performed using the StatsDirect® 2.6.8 statistical package. The extended evaluation of safety based on sources other than RCTs was performed. In the light of the analysis carried out it can be concluded that administered orally plus psychotherapy for alcohol-dependent patients results in a higher clinical effectiveness and comparable safety profile in comparison with acamprosate for a 1-year-long-observation treatment and placebo for both a short (12-16 weeks) and medium-term observation treatment. Statistical significances in favor of the intervention under evaluation were found both in the percentage of patients maintaining total abstinence as well as in the percentage of relapsed patients. Statistically significant in favor of naltrexone treatment when assessing too such endpoint as alcohol craving intensity assessment for the NAL/PSY vs ACA/PSY analysis in a long treatment period and for the NAL/PSY vs PL/PSY analysis in a short term.Long-term results (52 weeks) of the analysis quoted indicate on a comparable clinical efficacy (no statistical significance of results obtained) of the use of naltrexone and placebo in the group of alcohol-dependent patients undergoing psychotherapy.The adverse events related to naltrexone treatment are usually mild and transient. The most frequent ones are: headaches, sleep disorders, anxiety, nervousness, gastrointestinal disorders such as abdominal pain, nausea, vomiting. Summing up, the results of the analysis carried univocally prove that naltrexone administered in a 50mg dose a day is an effective and safe drug in the treatment of alcohol dependent patients who additionally undergo a psychotherapy.